The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors. AYAs who were diagnosed with cancer and have completed cancer treatment will be recruited for this study. This study will enroll 20 participants in total and will last approximately 3 months.
Checked against the public recordLast updated Feb 26, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Cedars-Sinai Medical Center
- Interventions being studied
- Behavioral: Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Cancer (all types) diagnosis between the ages of 15-39 * Between the ages of 18-39 during study participation * At least 3 months post-active treatment completion * Answers "no" to all questions on the Physical Activity Readiness Questionnaire * Not currently meeting physical activity guidelines per leisure-time physical activity participation questionnaire * Access to and ability to use a computer, tablet or phone device with internet access * Ability to understand and read English * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study Exclusion Criteria: * Hearing loss or vision impairment that would preclude the participant from accessing and using the app (use of hearing aids or visual aids is acceptable) based on self-report * Currently meeting physical activity guidelines (score of \>23 on Godin-Shephard Leisure-Time Physical Activity Questionnaire) * Currently pregnant, based on self-report * Patients with active treatment planned within the next 3 months. (Active treatment includes chemotherapy, biologic therapy, radiation therapy, surgery, and any combination.) Long-term hormonal/biologic treatments are acceptable except for AR-targeted therapies for prostate cancer. Participants with known metastatic disease, grade 3 or higher neuropathy, major surgery within 3 months of baseline visit, pregnancy of childbearing potential will be excluded.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cedars-Sinai Medical CenterLos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 26, 2025. Always confirm current availability with the study team.